🔎 Trials Near Me

Domov › Rak ledvic (renocelularni karcinom) › Connecticut

Klinične študije za Rak ledvic (renocelularni karcinom) v Connecticut

13 študij za Rak ledvic (renocelularni karcinom) išče udeležence na lokacijah v Connecticut.

Mesta v Connecticut

Uradno besedilo študije (angleško)

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

  • NEO-811 Connecticut Site, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07300241

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • Yale - New Haven Hospital, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06234605

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #62, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  • Local Institution - 0117, New Haven
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07293351

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

  • Yale University Cancer Center LAO, New Haven
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07516366

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Hartford HealthCare - Avon, Avon
  • Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
  • Smilow Cancer Hospital-Derby Care Center, Derby
  • in še 15
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06661720

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT05433142

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  • Yale University Hospital, New Haven
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 9. jul. 2026 · NCT03972657

Investigation of Lymph Node Biology in Kidney Cancer

  • Yale University, New Haven
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 16. jun. 2026 · NCT07038733

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

  • Yale University School of Medicine /ID# 225707, New Haven
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT04777994

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  • Yale School of Medicine, North Haven
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 28. apr. 2026 · NCT06413680

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

  • Yale University, New Haven
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. dec. 2025 · NCT04974671

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

  • Yale Cancer Center, New Haven
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 15. nov. 2024 · NCT04787042

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.